scientific advisory board

Dr. Ausiello is the Jackson Professor of Clinical Medicine at Harvard Medical School, Chief of Medicine at Massachusetts General Hospital, and Chief Scientific Officer of Partners Healthcare. He received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania.

He has made a substantial contribution to the knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks and currently serves as the co-editor of Cecil's Textbook of Medicine, now in its 23rd edition. A nationally recognized leader in academic medicine, Dr. Ausiello was elected to the Institute of Medicine of the National Academy of Science in 1999 and the American Academy of Arts and Sciences in 2003. Dr. Ausiello served as Chief of the MGH Renal Unit and oversaw its development into one of the most sought after research and training programs in the world.

As Chief of Medicine at MGH, a position he has held since 1996, he leads one of the strongest Departments of Medicine in the country with a clinical, research and education budget exceeding $600 million annually. He is closely involved with the Partners HealthCare System, linking the resources of the MGH, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute to provide comprehensive health care.

As an internationally recognized scientist, Dr. Ausiello has been the recipient of two MERIT awards from the National Institutes of Health and has served as a counsel member of th National Institute of Diabetes, Digestive and Kidney Diseases Advisory Council and the National Advisory Council on Aging.

Dr. Boucher has extensive experience in the study of the pathophysiology and therapy of chronic airways diseases, including cystic fibrosis. He is currently a William Rand Kenan Professor of Medicine at the University of North Carolina, the Chief of Pulmonary Medicine, Director of the UNC Cystic Fibrosis/Pulmonary Research and Treatment Center, and Co-Director of the UNC Gene Therapy Center. He has published more than 400 papers on all aspects of pulmonary medicine and cystic fibrosis. In addition, Dr. Boucher was a founder of Inspire Pharmaceuticals, a biotechnology company focused on developing novel nucleotide-based therapies for the treatment of lung disease.

Dr. Boucher is Co-Founder & Chairman of the Board of Parion, a privately held development-stage pharmaceutical company focused on the discovery and development of new treatments for pulmonary indications including cystic fibrosis, COPD, and bronchiectasis. He holds more than 30 patents focused on novel therapies of lung diseases. He received his BA from Yale University and his MD from Columbia University.

Dr. Calderwood, an infectious diseases specialist and Chief of the Infectious Disease (ID) Division at Massachusetts General Hospital, graduated from Harvard College and Harvard Medical School. He trained in medicine and ID at MGH, where he was chief resident in medicine. He is co-chair of the Training Council, Promotions Committee, and Medical Services a MGH. He teaches in the microbiology courses of both Harvard and New Pathway, as well as the ABS course, Modern Medical Microbe Hunters. He is Co-Editor-in-Chief of UpToDate, Infectious Diseases section.

Dr. Clapham is a leader in cell signal transduction, with particular expertise in ion channels andG protein-coupled receptors. As the Aldo R. Casteñada Professor of Cardiovascular Research at Children's Hospital of Boston, he is the hospital's director of Cardiovascular Research. He is also a professor of Neurobiology a Harvard Medical School, and a member of the American Academy of Arts and Sciences and the National Academy of Sciences.

Early in his career, David established his independent research laboratory in the Department of Medicine at Brigham and Women's Hospital of HMS. He earned an MD and PhD in Anatomy/Cell Biology from Emory University School of Medicine and an Electrical Engineering degree at the Georgia Institute of Technology. David was a senior Fulbright Fellow during his postdoctoral training with Erwin Neher at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. Dr. Neher is the co-inventor (with B. Sakmann) of the patch clamp technique for which he won a Nobel Prize.

Dr. Edwards is the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University, where his work focuses on the fields of fluid mechanics, interfacial transport phenomena, drug delivery, and aerosol science. His current research is supported by grants from the National Institutes of Health and the Bill and Melinda Gates Foundation, and includes the investigation of the fluid mechanical properties of the lung lining fluid that permit control of expired bioaerosol and mitigation of the spread of inhaled infectious disease, the development of novel antibiotic therapies for tuberculosis, and a new delivery platform for needleless childhood vaccines.

Dr. Edwards has published over 70 papers on the aerosol delivery of macromolecules to the lung and a variety of related subjects. He is a Fellow of the American Institute of Medical and Biological Engineering and a Member of the National Academy of Engineering. Dr. Edwards is a recipient of numerous awards including the Professional Progress Award of the American Institute of Chemical Engineers, and is a three time recipient of the Ebert Prize of the American Pharmaceutical Association.

He is a member of the Advisory Board at the Center for Civilian Biodefense Strategies at the Johns Hopkins University. He is also the founder of Advanced Inhalation Research (AIR) which was acquired by Alkermes, Inc., and Chairman of the Board of the international not-for-profit Medicine in Need (MEND).

Dr. Hickey is Professor of Molecular Pharmaceutics of the School of Pharmacy, and Biomedical Engineering of the School of Medicine, at the University of North Carolina at Chapel Hill. He obtained PhD (1984) and DSc (2003) degrees in pharmaceutical sciences from Aston University, Birmingham, UK. Following postdoctoral positions, at the University of Kentucky (1984-1988)

Dr. Hickey joined the faculty at the University of Illinois at Chicago. In 1990 he received the AAPS Young Investigator Award in Pharmaceutics and Pharmaceutical Technology. In 1993 he joined the faculty of the School of Pharmacy, UNC-CH. He is a Fellow of the Institute of Biology (2000), the American Association of Pharmaceutical Scientists (2003) and the American Association for the Advancement of Science (2005). He has published numerous papers and chapters in the pharmaceutical and biomedical literature, one of which received the AAPS Meritorious Manuscript Award in 2001. He has edited five texts on pharmaceutical inhalation aerosols and co-authored four others on Pharmaceutical Process Engineering, Particulate Science and Pharmaco-complexity.

Dr. Hickey is founder, President and CEO of Cirrus Pharmaceuticals, Inc. (since 1997), founder (2001, and formerly CSO, 2002-2007) of Oriel Therapeutics, Inc. (acquired by Sandoz Inc. 2010), past Chair of the Aerosols Expert Committee of the United States Pharmacopeia (2005-2010), current member of the Pharmaceutical Dosage Forms Expert Committee (2010-2015) and Program Director for Innovation and Translation Alliances of the not-for-profit, Medicine in Need (since 2009). Dr. Hickey leads a multidisciplinary research group in the field of pulmonary drug and vaccine delivery.

Dr. Langer is the Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. The only active member of all three U.S. National Academies (the National Academy of Sciences, the Institute of Medicine, and the National Academy of Engineering), Dr. Langer is one of 14 Institute Professors at MIT. His career has focused on pioneering work at the interface of biotechnology, drug delivery, and materials science, resulting in over 1000 articles and over 600 issued or pending patents worldwide. His patents have further been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology, and medical device companies.

Dr. Langer is a founder of over 20 successful companies, including Momenta, Alnylam, Transform Pharmaceuticals, Pervasis, and Advanced Inhalation Research (AIR). Dr. Langer has additionally served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.

Dr. Langer has received over 160 major awards including the 2006 United States National Medal of Science, the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world’s largest technology prize. Dr. Langer received his BS from Cornell University, and his ScD from the MIT, both in Chemical Engineering.

Dr. Palese is Professor of Microbiology and Chair of the Department of Microbiology at the Mount Sinai School of Medicine in New York. He has over 270 scientific publications that include research on the replication of RNA-containing viruses with a special emphasis on influenza viruses, which are negative-strand RNA viruses. Specifically, he established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals.

Dr. Palese also pioneered the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses Dr. Palese was elected to the National Academy of Sciences in 2000 for his seminal studies on influenza viruses. At present he serves on the editorial board for the Proceedings of the National Academy of Sciences and as an editor for the Journal of Virology.

Dr. Palese was president of the Harvey Society in 2004, president of the American Society for Virology in 2005 and he was a recipient of the Robert Koch Prize in 2006 and of the Charles C. Shepard Science Award in 2008.

Dr. Ulevitch joined 5AM Ventures as Venture Partner in February 2008. Prior to this date, he was Chairman of the 5AM Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute, La Jolla, California. He remains as Chairman Emeritus at The Scripps Research Institute.

For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He also serves as a scientific advisor to European life science venture capital fund, Aravis Ventures, and was previously an advisor to the Lombard Odier Immunology Fund, and has evaluated hundreds of biotechnology companies over the past fifteen years. Dr. Ulevitch received an A.B. from Washington and Jefferson College and a PhD in Biochemistry from the University of Pennsylvania.